ROS1 and non-small cell lung carcinoma: In this phase I/II study, we aimed to characterize the tolerability, safety, and antitumor activities of unecritinib in ROS1 inhibitor-naive patients with ROS1-rearranged advanced NSCLC and other selected advanced solid tumors who had failed standard chemotherapy.